| Title: | Novel Azaindazole Sulfonamides Inhibitors of Serum and Glucocorticoid Regulated Kinase | ||
| Patent/Patent Application Number: | WO 2014/140065 A1 | Publication date: | September 14, 2014 |
| Priority Application: | EP 2013–305283 | Priority date: | March 13, 2013 |
| Inventors: | Nazare, M.; Halland, N.; Schmidt, F.; Kleeman, H. W.; Weiss, T.; Saas, J.; Struebing, K. | ||
| Assignee Company: | Sanofi, France | ||
| Disease Area: | Degenerative joint disorders, inflammation, and cancer | Biological Target: | Serum and glucocorticoid regulated kinase (SGK-1) |
| Summary: | The present application claims a series of azaindazole sulfonamides as inhibitors of SGK-1 kinase. The compounds of the invention are potentially useful in the treatment of various disease states such as cardiovascular diseases, inflammation, ostheoarthritis, diabetes, and cancer. | ||
| Important Compound Classes: |  |
||
| Key Structures: |  |
||
| Biological Assay: | The enzymatic activity of the compounds was evaluated in a substrate phosphorylation assay. The cellular activity of the compounds was measured in U2OS cells overexpressing recombinant SGK-1 and GSK2beta. | ||
| Pharmacological Data: |  |
||
| Synthesis: | The synthesis of 699 compounds is described. | ||
The authors declare no competing financial interest.